Microbiota-derived Trimethylamine N-oxide Predicts Cardiovascular Risk After STEMI.

ABSTRACT: Trimethylamine N-oxide (TMAO), a metabolite derived from the gut microbiota, is proatherogenic and associated with cardiovascular events. However, the change in TMAO with secondary prevention therapies for ST-segment elevation acute myocardial infarction (STEMI) remains unclear. The purpose of this study was to investigate the sequential change in TMAO levels in response to the current secondary prevention therapies in patients with STEMI and the clinical impact of TMAO levels on cardiovascular events We included 112 STEMI patients and measured plasma TMAO levels at the onset of STEMI and 10 months later (chronic phase). After the chronic-phase assessment, patients were followed up for cardiovascular events. Plasma TMAO levels significantly increased from the acute phase to the chronic pha

SUBMITTER: Matsuzawa Y 

PROVIDER: S-EPMC6690996 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature